Inclusion Criteria:

- Histologically confirmed gastric adenocarcinoma in tissue/cell

- Recurrent or metastatic gastric cancer that has progressed following first- line
therapy

- Patients must be ≥18 years of age.

- ECOG performance status ≤ 2

- At least one lesion (measurable or non-measurable but evaluable) according to RECIST
criteria

- Normal organ and bone marrow function measured within 2 weeks prior to administration
of study treatment as defined below: Haemoglobin ≥ 9.0 g/dL White blood cells (WBC) ≥
3000/µL Absolute neutrophil count (ANC) ≥ 1500/µL Platelet count ≥ 100 x 103/µL Total
bilirubin ≤ 1.5 x upper normal limit (UNL) Creatinine clearance ≥ 60 ml/min or Serum
creatinine ≤ 1.5 x UNL AST (SGOT)/ALT (SGPT) ≤ 2.5 x UNL unless liver metastases are
present in which case it must be ≤ 5x UNL

- Life expectancy ≥ 12 weeks.

- Written informed consent

- Provision of informed consent for genetic research (In case of optional genetic
research)

Exclusion Criteria:

- More than one prior chemotherapy regimen for the treatment of gastric cancer in the
metastatic or recurrent setting.

- Treatment with any investigational product during the last 14 days (or a longer
period depending on the defined characteristics of the agents used).

- Any previous treatment with a taxane, including paclitaxel and docetaxel or
irinotecan, in the metastatic or recurrent setting.

- Patients with second primary cancer, except: adequately treated non- melanoma skin
cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
curatively treated with no evidence of disease for ≥5 years.

- Patients receiving any systemic chemotherapy, radiotherapy (except for palliative
reasons), within 2 weeks from the last dose prior to study treatment (or a longer
period depending on the defined characteristics of the agents used).

- Ongoing toxicities (>CTCAE grade 2) caused by previous cancer therapy.

- Clinically proven gastric outlet obstruction or CTCAE grade 3 or grade 4 upper GI
bleeding

- Medically uncontrolled, clinically significant heart disease or infection

- Patients with symptomatic uncontrolled brain metastases.

- Major surgery within 2 weeks of starting study treatment and patients must have
recovered from any effects of any major surgery.

- Women who have pregnancy potential or willing to pregnant. Pregnant and breastfeeding
women.

- Others Poor medical risk due to a serious, uncontrolled medical disorder, non-
malignant systemic disease or active, uncontrolled infection Any psychiatric
disorder that prohibits obtaining informed consent and regular follow-up.
Inappropriate patient for subjects of this study on investigator's judgment